What potential treatments are in development?

Treatment Pipeline

pipeline

This information is publicly available and reshared here for informational purposes only. It is not medical advice. FARA does not endorse, control, or govern the research pipeline programs.

Potential treatments for FA are grouped based on mechanism of action and stage of development (in the country where the candidate is furthest in its development process).

FARA helps advance treatments through funding, advocacy, patient engagement and/or collaboration. We believe the most effective treatment will likely be a combination of two or more therapies. To learn more about the stages of drug development, click here.

Active – programs currently under development and supported by the listed sponsor.
Inactive – programs no longer in development because of lack of safety or efficacy or for which the sponsor has paused recruitment because of resource constraints and for which there is not a clear path forward.
  • Reset
Discovery
Finding potential therapies / drugs
Pre-clinical development
Testing in laboratory
Regulatory Submission
Permission to enter clinic
Phase I
Human safety trial
Phase II
Human safety and efficacy trial
Phase III
Definitive trial
Request for Approval
Permission to enter market
Available to patients

Improve Mitochondrial Function & Reduce Oxidative Stress

Omaveloxolone (Brand Name: SKYCLARYS for >16yo)

Biogen

Learn more
Available to patients >16yo; Phase 3 <16yo
Available to patients >16yo; Phase 3 <16yo

Improve Mitochondrial Function & Reduce Oxidative Stress

Vatiquinone (PTC-743)

PTC Therapeutics

Learn more
FDA Decision
FDA Decision

Improve Mitochondrial Function & Reduce Oxidative Stress

Elamipretide (Brand Name FORZINITY™ for Barth Syndrome)

Children’s Hospital of Philadelphia

Learn more
Phase I/II
Phase I/II

Improve Mitochondrial Function & Reduce Oxidative Stress

NAD+ and Exercise in FA

Children’s Hospital of Philadelphia

Learn more
Phase II
Phase II

Modulation of Frataxin Controlled Metabolic Pathways

Dimethyl Fumarate

University of Federico II

Learn more
Phase II
Phase II

Frataxin Replacement, Stabilizers, or Enhancers

Nomlabofusp (CTI-1601)

Larimar Therapeutics

Learn more
Phase II
Phase II

Increase Frataxin Gene Expression

DT-216P2

Design Therapeutics

Learn more
Phase I/II
Phase I/II

Cell Therapy

PPL-001

Papillon Therapeutics

Learn more
Pre-clinical
Pre-clinical

Gene Addition

LX2006 Gene Therapy

Lexeo Therapeutics

Learn more
Phase I/II
Phase I/II

Gene Addition

SGT-212

Solid Biosciences

Learn more
Phase 1b
Phase 1b

Gene Addition

NBIB-223 (frataxin)

Neurocrine Biosciences / Voyager Therapeutics

Learn more
Pre-clinical
Pre-clinical

Gene Addition

CAP-004

Capsida Biotherapeutics

Learn more
Pre-clinical
Pre-clinical